Literature DB >> 8891480

Mediation of signal transduction in keratinocytes of human middle ear cholesteatoma by ras protein.

C C Huang1, C T Chen, T S Huang, H Shinoda.   

Abstract

Immunolocalization was used to investigate the distribution of ras protein in both congenital and acquired cholesteatoma tissues. A pathological feature of middle ear cholesteatoma included accumulation of keratin debris due to active proliferation and differentiation of keratinocytes. Ras protein localized to the inner plasma membrane and cytoplasm of keratinocytes in all of the epithelial layers in both congenital and acquired cholesteatoma specimens. Keratinocytes in the basal layer were stained more intensely than their differentiated counterparts. Findings also demonstrated that receptors for epidermal growth factor, fibroblast growth factor, and plateletderived growth factor were present in the plasma membrane of keratinocytes. C-jun, a transcription factor was found in the nuclei of keratinocytes of the cholesteatoma epithelium. These findings indicate that ras protein plays a pivotal role in a signal transduction cascade between growth factor receptors in the plasma membrane and the transcription factor, c-jun, in the nuclei of keratinocytes during the growth of cholesteatoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891480     DOI: 10.1007/bf00168488

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  12 in total

Review 1.  Ras in signal transduction.

Authors:  T Satoh; Y Kaziro
Journal:  Semin Cancer Biol       Date:  1992-08       Impact factor: 15.707

Review 2.  Protein prenylation: key to ras function and cancer intervention?

Authors:  R Khosravi-Far; A D Cox; K Kato; C J Der
Journal:  Cell Growth Differ       Date:  1992-07

Review 3.  Ras C-terminal processing enzymes--new drug targets?

Authors:  J B Gibbs
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

4.  The pathway to signal achievement.

Authors:  S E Egan; R A Weinberg
Journal:  Nature       Date:  1993-10-28       Impact factor: 49.962

Review 5.  The Ras signal transduction pathway.

Authors:  R Khosravi-Far; C J Der
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

6.  Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs.

Authors:  L S Ulsh; T Y Shih
Journal:  Mol Cell Biol       Date:  1984-08       Impact factor: 4.272

7.  Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death.

Authors:  H Shinoda; C C Huang
Journal:  Laryngoscope       Date:  1995-11       Impact factor: 3.325

8.  Continuous c-fos expression precedes programmed cell death in vivo.

Authors:  R J Smeyne; M Vendrell; M Hayward; S J Baker; G G Miao; K Schilling; L M Robertson; T Curran; J I Morgan
Journal:  Nature       Date:  1993-05-13       Impact factor: 49.962

9.  Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry.

Authors:  M C Willingham; I Pastan; T Y Shih; E M Scolnick
Journal:  Cell       Date:  1980-04       Impact factor: 41.582

10.  Expression of cytokeratins 13 and 16 in middle ear cholesteatoma.

Authors:  H Sasaki; C C Huang
Journal:  Otolaryngol Head Neck Surg       Date:  1994-03       Impact factor: 3.497

View more
  2 in total

1.  Upregulation of phosphorylated HSP27, PRDX2, GRP75, GRP78 and GRP94 in acquired middle ear cholesteatoma growth.

Authors:  Kuen Yao Ho; Tai Sheng Yeh; Han Hsiang Huang; Kuo Feng Hung; Chee Yin Chai; Wan Tzu Chen; Shih Meng Tsai; Ning Chia Chang; Chen Yu Chien; Hsun Mo Wang; Yu Jen Wu
Journal:  Int J Mol Sci       Date:  2013-07-11       Impact factor: 5.923

Review 2.  Review of potential medical treatments for middle ear cholesteatoma.

Authors:  Matthias Schürmann; Peter Goon; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.